Investment Memo – Roche Holding AG (Pharmaceutical Division / “Roche Pharma”) 1. Executive Summary Roche is a leading global pharmaceutical and diagnostics company with a strong focus on oncology, immunology, neuroscience, and rare diseases.Read more
Roche is betting on a wave of new medicines and more advanced lab tests to replace older products and keep growth going, while also pushing for smarter and more efficient research and operations. The big question is whether these new launches arrive on time and win share amid pricing pressure, patent cliffs, and currency swings.Read more
Roche is betting on a wave of new medicines and major U.S. investment to keep demand steady, but fierce competition, pricing pressure, and big development programs could blunt the payoff. See why some analysts think the market may be expecting too much even as the business continues to improve.Read more
Catalysts About Roche Holding Roche is a global healthcare company focused on pharmaceuticals and diagnostics across oncology, neurology, immunology, ophthalmology and cardiometabolic diseases. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
